Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Abstract</jats:title> <jats:p>The text in <jats:italic>Chapter 4, Results, Main findings, Complications</jats:italic> has been replaced with the following text [these data do not alter the economic modelling (which was based on the correct data), nor the inferences from the trial that the FeverPAIN score is the optimal management approach]:<jats:list list-type="simple"> <jats:list-item> <jats:p>There were very few complications in any trial groups: during the first trial phase there were two cases of otitis media and one case of cellulitis in the clinical score group and one case of cellulitis in the delayed antibiotic group; during the second trial phase (when using the FeverPAIN score) there were two cases of quinsy in the delayed antibiotic group and one case of otitis media in the RADT group.</jats:p> </jats:list-item> </jats:list> </jats:p>

Original publication






National Institute for Health Research




103 - 104